天然PCSK9抑制剂在心血管疾病中的研究进展

ardiovascular disease (CVD) is still the leading cause of death worldwide, and new prevention and treatment strategies are urgently needed. Proprotein convertase subtilisin Keratin Type 9 (PCSK9), as a vital modulator of low-density lipoprotein cholesterol (LDL-C), plays a key role in the progression of CVD. In 2015, monoclonal antibodies Evolocumab and Alirocumab targeting PCSK9 were approved for clinical use, but their low cost-effectiveness and inconvenient administration have limited clinical use, thus there is a need for the development of orally available and low-cost small-molecule inhibitors of PCSK9. Natural compounds have rich sources and diverse structures, which have great drug development potential and are an important source for the development of small molecule inhibitors of PCSK9. In this review, we combined the latest literature to explore the role of PCSK9 in cardiovascular diseases and the research progress of natural products as PCSK9 inhibitors.